



## Inhalation & Nasal Product Capabilities


## Overview

The Global Burden of Disease data suggests that respiratory diseases contribute to high morbidity and mortality and is third leading cause of death. Chronic obstructive pulmonary disease (COPD) & asthma lead this therapeutic category. Both in treatment and management, inhalation drug delivery methods have attracted tremendous interest in the past two decades. To get both local and systemic effects; Inhalation therapy has several advantages over other drug delivery routes; large surface area available in alveolar sacs and high vascularization make the lungs an appropriate site of drug absorption

Inhalation clinical studies are complex and challenging studies. When stakes are high, you need partner with deep therapeutic & regulatory expertise.

Cliantha Research is full service global CRO with a unique approach to clinical development & is well suited to manage some of the industry's most complex and challenging Inhalation clinical studies.

## KEY CHALLENGES OF CLINICAL STUDY FOR INHALATION DRUGS



## Accelerate your drug launch with Cliantha Research's Infrastructure and Expertise

We ensure that your inhalation study is conducted with the highest level of compliance to regulatory requirement. We ensure precise dosing by screening the volunteers based on specific respiratory parameters and train them on route of administration. Our study infrastructure includes negative air chambers to ensure accuracy of dosing and avoid cross contamination..


### CLINICAL STUDIES OF KEY MOLECULES

- Albuterol Sulfate (MDI)
- Alcaftadine (Nasal Spray)
- Azelastine Hydrochloride/ Fluticasone Propionate (Nasal Spray)
- Budesonide + Formoterol Fumarate Dihydrate (MDI)
- Fluticasone Propionate HFA (MDI)
- Indacaterol/ Glycopyrronium (DPI)
- Ipratropium Bromide HFA (MDI)
- Methylcobalamin (Nasal Spray)
- Olopatadine Hydrochloride (Nasal Spray)
- Tiotropium (DPI)

### Negative Pressure Room



### CLIANTHA ADVANTAGE



Contact Cliantha today for more information about how we can enable you to make product launch decisions faster

**For more information contact:**  
**Abhishek Patel, GM-Business Development (Early Phase)**  
**[info@cliantha.com](mailto:info@cliantha.com)**